#United States #Oakland #NFL #NextGen Jane #menstrual fluid

NextGen Jane's Groundbreaking Research

NextGen Jane, Inc. has made significant strides in women's health with a pivotal study that uncovers the relationship between menstrual fluid, estrogen levels, and a key marker of neurological injury known as neurofilament light chain (NfL).

Study Overview

Presented during the 2026 American Academy of Neurology (AAN) Annual Meeting in Chicago, the research highlighted how NfL—a widely recognized indicator of neuroaxonal damage—can be detected in menstrual samples, illuminating a new facet of biological signals present in these fluids. In a comprehensive analysis of 99 tampon-collected samples from 89 participants, researchers utilized advanced automated immunoassay technology from Siemens Healthineers to successfully identify NfL in nearly all samples.

Methodology and Findings

To account for variations in blood content within the menstrual samples, a novel transferrin-based normalization framework was established. This allowed researchers to demonstrate a reliable correlation between NfL levels and estradiol, independent of the blood proportions present in the samples. Remarkably, this discovery suggests that menstrual fluid may convey deeper, biologically relevant neurological signals overlooked by traditional blood testing methods.

Complementary transcriptomic analyses further validated these findings, indicating a significant variation in the NEFL gene expression along the menstrual cycle's inflammatory resolution path. This data underpins the notion that menstrual fluid may hold critical neurological insights.

Implications for Future Research

Ridhi Tariyal, CEO and co-founder of NextGen Jane, remarked, "This correlation between NfL and estrogen levels signifies that there is genuine biological activity present in menstrual fluid, not mere contamination.” The implications of this research extend beyond basic science; the company plans to implement longitudinal studies to explore whether NfL and other neurological biomarkers tracked in menstrual fluid could provide valuable information on disease activity for conditions like multiple sclerosis.

Stephen Gire, the Chief Science Officer at NextGen Jane, stated, “Leveraging the menstrual cycle provides a unique framework for ongoing biological assessment, allowing us to gather samples from the same individual consistently.”

Innovation in Women's Health

NextGen Jane is redefining the landscape of immunology and inflammation-related drug development. By considering menstruation as a crucial biological event, the company harnesses non-invasive menstrual sampling to discover and utilize molecular data that have historically been underrepresented in traditional medical research. This groundbreaking approach sets the groundwork for enriched diagnoses, targeted therapies, and enhanced clinical strategies.

Through adopting new tools and methodologies, such as the partnership with Siemens Healthineers' sensitive NfL assays, NextGen Jane is pioneering a path for further investigations into the trajectories of neurological biomarkers.

Conclusion

Though the NfL assay is not yet available commercially in the U.S., the findings presented illuminate a promising future in how menstruation could be viewed as a means to better understand and predict neurological health. As research progresses, we can expect that menstrual fluid will become an essential resource in women's healthcare, bridging gaps in diagnostics and potentially transforming how we address various neurological conditions. For more details, visit NextGen Jane's website.